Rabeprazole Applications

Only available on StudyMode
  • Download(s) : 149
  • Published : September 16, 2012
Open Document
Text Preview
Online Submissions: http://www.wjgnet.com/1948-9358office wjd@wjgnet.com doi:10.4239/wjd.v2.i12.217

World J Diabetes 2011 December 15; 2(12): 217-220 ISSN 1948-9358 (online) © 2011 Baishideng. All rights reserved.


Are proton pump inhibitors a new antidiabetic drug? A cross sectional study Diana Boj-Carceller, Pilar Bocos-Terraz, Miguel Moreno-Vernis, Alejandro Sanz-Paris, Pablo Trincado-Aznar, Ramón Albero-Gamboa Diana Boj-Carceller, Alejandro Sanz-Paris, Pablo TrincadoAznar, Ramón Albero-Gamboa, Endocrinology and Nutrition Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Pilar Bocos-Terraz, Hormonal Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Miguel Moreno-Vernis, Clinical Documentation and Archives Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Author contributions: Boj-Carceller D and Bocos-Terraz P conceived and designed the study, performed the analysis and interpretation of data and wrote the manuscript; Moreno-Vernis M collected the data and gave administrative support; Sanz-Paris A, Trincado-Aznar P and Albero-Gamboa R gave a critical revision of the article; all authors approved the version of the manuscript to be published. Correspondence to: Diana Boj-Carceller, Dr�, Endocrinology and Nutrition Unit, Hospital Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain. dianna_bc@hotmail.com Telephone: +34-976-765500-2164 Fax: +34-976-765509 Received: July 4, 2011 Revised: October 2, 2011 Accepted: October 10, 2011 Published online: December 15, 2011

-0.��. People who used PPIs with some type of insu0.��. lin therapy had a HbA1c reduction by -0.�%, 95% CI: -0.12 to -1.��. �or the rest of subgroup analysis based 1.��. on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels. CONCLUSION: PP�s seems to be consistentl� associated with better glycemic control in type 2 diabetes. �bA�c reduction observed is similar to incretin-based therapies� © 2011 Baishideng. All rights reserved.

Key words: Proton pump inhibitors; Diabetes mellitus; Drug therap�; ��pogl�cemic agents; �ncretins Peer reviewer: Arulmozhi D Kandasamy, Dr., Department of Pharmacology, University of Alberta, 4-30 Heritage Medical Research Centre, Cardiovascular Research Centre, Edmonton T6G 2S2, Canada Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2011; 2(12): 217-220 Available from: URL: http:// www.wjgnet.com/1948-9358/full/v2/i12/217.htm DOI: http:// dx.doi.org/10.4239/wjd.v2.i12.217

AIM: To investigate the e��ect o� proton pump inhibio roton tors �PP�s�� on gl�cemic control ��bA�c�� in t�pe �� diaPP�s�� �� betic patients� METHODS: A cross-sectional stud� o� consecutive inpatients admitted to hospital in an� department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis o� h�pergl�cemic decompensation, diabetic onset or pregnanc�� �t compared �bA�c levels o� those taking PP�s and those not� RESULTS: A total of 97 patients were recruited. The average HbA1C level was 7.0% ± 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to : 0.12

Proton pump inhibitors (PPIs) have become one of the most commonly prescribed class of drugs whose overall safety profile is unquestionable[1]. PPIs are mainly used to treat symptoms of gastroesophageal reflux disease and gastritis, but also to treat peptic ulcers (duodenal and gastric), drug-induced ulcers and to promote healing of erosive esophagitis[2]. They decrease secretion of gastric acid by blocking



December 15, 2011|Volume 2|Issue 12|

Boj-Carceller D et al � Antidiabetic properties o� proton pump inhibitors

the last enzyme in the system that actively transports acid from gastric parietal...
tracking img